Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Change in Cash (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Change in Cash for 5 consecutive years, with -$7.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 4.64% to -$7.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.7 million, a 287.56% decrease, with the full-year FY2024 number at $18.8 million, up 284.61% from a year prior.
  • Change in Cash was -$7.7 million for Q3 2025 at Lyra Therapeutics, down from -$2.0 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $88.0 million in Q2 2022 to a low of -$77.0 million in Q4 2022.
  • A 5-year average of -$2.7 million and a median of -$8.1 million in 2024 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 2892.28% in 2022; the steepest drop was 522.04% in 2022.
  • Lyra Therapeutics' Change in Cash stood at -$12.4 million in 2021, then plummeted by 522.04% to -$77.0 million in 2022, then surged by 96.76% to -$2.5 million in 2023, then soared by 771.93% to $16.8 million in 2024, then plummeted by 146.07% to -$7.7 million in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Change in Cash are -$7.7 million (Q3 2025), -$2.0 million (Q2 2025), and -$8.8 million (Q1 2025).